Rayno Life Science Portfolio: DX and Tools Q3 Review-Caution

We are in bit of a lull here as the sumer doldrums post earnings has hit many diagnostic stocks. Most stocks in the sector have hit their highs early in July prior to the July AACC Meeting. We will look for drivers for Q4 appreciation, a time of bullish seasonality. Within our focus list here is a brief summary:

New positions:

http://fieldandfire.com/wp-content/plugins/restaurantpress/assets/css/restaurantpress-layout.css?ver=1.6.0 Buy ThermoFisher (TMO $56.43) at $53.50. New.

Add to  http://arc-theatre.com/?thh=250 Alere ALR $18.90) Illumina (ILMN $41.68) and Luminex (LMNX $19.25) on weakness.

Cepheid http://azteenmagazine.com/2014/04/?s= (CPHD $36.12)  buying window near $32 was hit in late July. Still it is the # 1 growth stock in the sector although now the stock is very expensive and not profitable.

Strong Holds: Abaxis (ABAX $38.39), ExactSci (EXAS $9.97), Qiagen (QGEN $17.59), and Quidel (QDEL $16.85).

Weak Holds: Neogen (NEOG $40.23), Response Genetics (RGDX $0.80), and Sequenom (SQNM $3.69).

Under review: ChemBio (CEMI $4.59) and Hologic (HOLX $19.47).

As we have stated before, Biopharmaceuticals are the preferred sector to trade and invest in the life sciences although indices IBB ($ 135.84) are looking toppy. These stocks are rallying big today.

No comments yet.

Leave a Reply